Intravitreal ranibizumab (Lucentis) for choroidal neovascularization associated with Stargardt’s disease
- First Online:
- Cite this article as:
- Querques, G., Bocco, M.C.A., Soubrane, G. et al. Graefes Arch Clin Exp Ophthalmol (2008) 246: 319. doi:10.1007/s00417-007-0689-z
To describe a young patient with choroidal neovascularization, associated with Stargardt’s disease, who underwent treatment with intravitreal ranibizumab.
A 26-year-old man with a diagnosis of Stargard’s disease presented at our department for sudden decreased vison in his right eye (20/800). Upon a complete oplthamologic examination, including fluorescein angiography (FA), indocyanine green angiography (ICGA) and optical coherence tomography (OCT), the patient was diagnosed with subfoveal CNV of the right eye. Owing to the subfoveal localization of the CNV, intravitreal ranibizumab injection was performed on this young patient.
Three months after the last intravitreal injection of ranibizumab, fundus biomicroscopy, FA, ICGA and OCT revealed the CNV closure and total resolution of the associated cistoid macular edema and serous retinal detachment, with no recurrence and no complication from the intravitreal injection of ranibizumab. Visual acuity improved only to 20/400.
Intravitreal ranibizumab injection seems to induce total regression of CNV complicating Stargardt’s disease. Further investigations are required to confirm our results.